B-Cell Maturation Antigen Targeted Therapy with Top Players Celgene, GlaxoSmithKline, Novartis AG, Juno Therapeutics, Gilead Sciences
According to Leukemia Research by Elsevier, as of 2014, the incidence of multiple myeloma is estimated to be around 120,000 cases per year, with a global prevalence of over one million cases.
View full press release